Nurix Therapeutics (NRIX) Equity Average: 2019-2025
Historic Equity Average for Nurix Therapeutics (NRIX) over the last 5 years, with Aug 2025 value amounting to $409.9 million.
- Nurix Therapeutics' Equity Average rose 9.67% to $409.9 million in Q3 2025 from the same period last year, while for Aug 2025 it was $409.9 million, marking a year-over-year increase of 9.67%. This contributed to the annual value of $363.7 million for FY2024, which is 44.29% up from last year.
- According to the latest figures from Q3 2025, Nurix Therapeutics' Equity Average is $409.9 million, which was down 11.70% from $464.3 million recorded in Q2 2025.
- Nurix Therapeutics' Equity Average's 5-year high stood at $504.0 million during Q1 2025, with a 5-year trough of $184.6 million in Q1 2024.
- Its 3-year average for Equity Average is $334.4 million, with a median of $288.9 million in 2023.
- Its Equity Average has fluctuated over the past 5 years, first plummeted by 36.09% in 2024, then surged by 172.97% in 2025.
- Nurix Therapeutics' Equity Average (Quarterly) stood at $358.8 million in 2021, then declined by 9.93% to $323.1 million in 2022, then plummeted by 32.79% to $217.2 million in 2023, then skyrocketed by 108.11% to $451.9 million in 2024, then increased by 9.67% to $409.9 million in 2025.
- Its Equity Average stands at $409.9 million for Q3 2025, versus $464.3 million for Q2 2025 and $504.0 million for Q1 2025.